Objective. The clinical signi®cance of the presence of B19 DNA in patients with SLE was studied.
Human parvovirus B19 (B19) was discovered in the UK in 1975 w1x and has been associated with a variety of clinical manifestations, including rash, thrombocytopenia, leukopenia, fetal wastage, hypocomplementaemia, autoimmune haemolytic anaemia, arthritis and vasculitis w2±6x. It is the causative agent of erythema infectiosum (EI). In addition, B19 infection can be associated with elevated levels of antinuclear antibody, anti-doublestranded DNA antibody, antineutrophil cytoplasmic antigens and anti-cardiolipin w7x. B19 is a small, nonenveloped virus containing a single-stranded DNA of 5600 nucleotides and composed of two capsid proteins, VP1 (781 amino acids) and VP2 (554 amino acids), and a non-structural protein, NS1 w8±10x. It targets early erythroid progenitor cells. It requires rapidly dividing cells in order to replicate. The cellular receptor is the P antigen (globoside, a glycosphingolipid), expressed in most individuals on mature erythrocytes and other cells w11x. B19 infection is found world-wide in persons of all ages. Most people become infected at some time during their life, up to 15% of individuals developing infection between 1 and 5 yr of age, 15±60% between the ages of 5 and 19 yr, and 30±60% in adulthood w12±13x.
The detection of anti-VP1 and anti-VP2 antibodies is the basis for the diagnosis of acute or past B19 virus infections. The dominant humoral immune response is to VP2 during early convalescence and to VP1 during late convalescence. Anti-VP1 and anti-VP2 antibodies play a major role in limiting B19 infection in man w14x. Antibodies against NS1 may have utility as an indicator of chronic or persistent forms of B19 virus infection w15x.
The association of B19 infection with autoimmune diseases, including systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), Sjo È gren's syndrome (SS), primary biliary cirrhosis (PBC) and polymyositis (PM), has been suggested w5, 6, 16±19x, although the exact relationship between the infection and these disorders is not understood. Recently, it has been suggested that B19 exacerbates or even induces SLE w20±22x. There are striking analogies between the clinical features and haematological ®ndings of SLE and those of B19 infection. It was the aim of this study to investigate the role and clinical signi®cance of B19 infection in patients with SLE.
Materials and methods

Patients
One hundred and ®fty-nine serum samples were tested for parvovirus B19 infection by DNA detection with the nested polymerase chain reaction (PCR). Serum samples were collected from four patients with EI, 72 patients with SLE, 23 with RA, 18 with SS, eight with Raynaud's phenomenon (RP), ®ve with PM and ®ve with PBC. Twenty-two normal, age-and sex-matched subjects were used as a control group. The treatment of SLE depended on the severity of the disease. The patients were treated more aggressively if the disease was active. Of the 72 SLE patients, 41 received either low-dose prednisolone treatment (( 15 mg daily) anduor hydroxychloroquine, 11 received moderate-dose prednisolone (16±40 mg daily) and azathioprine treatment, and 20 received moderatedose prednisolone anduor cyclophosphamide treatment. All patients were followed up at Chung Shan Medical and Dental College Hospital, Taichung, Taiwan, and were diagnosed using the following criteria: SLE according to the 1982 revised criteria w23x; RA according to the 1987 American Rheumatism Association revised criteria w24x; SS according to the American College of Rheumatology criteria w25x; PM as described by Bohn and Peter w26x; and PBC as described by Williamson et al. w27x .
DNA puri®cation and PCR ampli®cation
For ampli®cation of B19 DNA by nested PCR w28x, DNA was extracted using the QIA Amp kit (Qiagen, Hilden, Germany) as directed by the manufacturer. In the ®rst round of ampli®cation, 0.2 mM of nucleotide primers corresponding to nucleotides 2381±2400 (B19SI) and 2781±2800 (B19ASI) (59-CCTTTTCTGTGCTAA-CCTGC-39 and 59-CCCAGGCTTGTGTAAGTCTT-39 respectively) were used. Two microlitres of each sample was used in a 50 ml reaction containing 5 ml of 10 3 buffer (500 mM Tris±HCl, pH 8.7, 50 mM NH 4 Cl, 20 mM MgCl 2 , 400 mM KCl, 1% Triton X-100), 4 ml of 25 mM dNTP, 1 unit of Tth DNA polymerase (AcuGen Systems, Boston, MA, USA) and 36 ml water. The reaction was overlaid with mineral oil. After an initial denaturation step of 5 min at 948C, 38 cycles were performed at 948C for 45 s, 548C for 45 s and 728C for 1 min. After the ®rst round of ampli®cation, 2 ml of the ®rst PCR product was added to the second-round PCR mixture containing 2 mM of each oligonucleotide primer corresponding to nucleotides 2429±2448 (B19SII) and 2730±2751 (B19ASII) (59-AAAGCTTTGTAGATTAT-GAG-39 and 59-GGTTCTGCATGACTGCTATGG-39 respectively). Then 25 cycles of ampli®cation were performed using the cycling parameters described. Subsequently, the nested PCR products of size 322 base pairs (bp) were con®rmed on 1% agarose gel. Negative controls were also included in each PCR reaction. The nested PCR was used as it eliminates non-speci®c background and thus gives a clearer ®nal product. Because of the high sensitivity of the nested PCR reaction used, stringent precautions were taken to avoid the risk of false-positive results.
Restriction mapping
One hundred microlitres of the nested PCR products of the B19-positive samples was analysed by the restriction endonucleases AluI and AcsI. The samples were loaded on a 1% TAE (Tris-acetateuEDTA) gel in TAE buffer for electrophoresis. The DNA fragments were cut and puri®ed with the Qiagen PCR puri®cation kit according to the manufacturer's instructions. Aliquots containing 1 mg of PCR products were digested with AluI (AluI site 2432, 2496, 2552) or AcsI (AcsI site 2894, 2517) with 10 units of enzyme for 4 h, and were separated on a 5% acrylamide gel. After electrophoresis, the DNA fragment was stained with ethidium bromide and excised under UV light.
Southern blot analysis. The procedure was as described by Sambrok et al. w29x. The PCR products were electrophoresed on a 1.5% TAE gel in TAE buffer. After electrophoresis, the DNA was transferred to a nylon membrane by capillary blotting. The gel was pretreated with an alkaline solution (0.2 N NaOH and 0.6 M NaCl) for 30 min and treated with Tris buffer (1.0 M Tris, pH 7.4, and 0.6 M NaCl) for another 30 min. Prehybridization was performed by treating the membrane with 5 3 Denhardt's solution, 100 mguml fragmented salmon sperm DNA and 20 mguml polyvinylpyrrolidone (Sigma) and 63 SSC (0.9 M NaCl and 0.09 M sodium citrate) at 558C for 5 h. The solution was replaced with a fresh hybridization solution of 5 3 Denhardt's solution, 6 3 SSC, 100 mguml fragmented salmon sperm DNA and 0.5% sodium dodecyl sulphate (SDS) containing 4 3 10 5 c.p.m.uml of w 32 PxATP end-labelled B19SIII oligonucleotide probe (59-CAGA-CTTAGAGCTTATTCAAATAT-39). After 12 h of hybridization at 558C with rotation, the nylon membrane was washed ®ve times with 2 3 SSC solution containing 1% SDS at 558C for 30 min and ®ve times with 0.5 3 SSC solution containing 1% SDS at 608C for 30 min. The membrane was air-dried and exposed on Kodak x-AR ®lm overnight at 2 708C.
Detection of B19 IgM and IgG antibodies
The B19 IgM antibody (Parvoscan-B19 TM IgM, EuroDiagnostica, Ideon, Sweden) and B19 IgG antibody (Parvoscreen-B19 TM IgG, Euro-Diagnostica) w30x were analysed by ELISA (enzyme-linked immunosorbent assay) against B19 VP1 and VP2 structural proteins according to the manufacturer's instructions.
Statistics
Statistical analysis was done with the x 2 test.
Results
Parvovirus B19 DNA was identi®ed in patients with EI and SLE We used nested PCR to test for the presence of B19 DNA in the blood of patients with a variety of autoimmune diseases, including SLE, RA, SS, RP, PBC, PM and EI. B19 DNA was detected in ®ve of six serum samples from four patients with EI and 17 of 72 SLE serum samples. As shown in Fig. 1 , lanes 3±4, 9 and 16±17 were positive for B19 DNA with the 322 bp nested PCR products. Table 1 shows a summary of data from patients with B19 DNA identi®ed by PCR. Only sera from patients with SLE and EI were found to have B19 DNA. None of the patients with RA, RP, SS, PM or PBC and none of the normal controls was found to have B19 DNA. Anti-parvovirus B19 IgG and IgM were detected in only one (5.9%) and two (11.8%) of 17 serum samples from SLE patients with B19 DNA respectively, whereas anti-parvovirus B19 IgG and IgM were detected in 27 (49.1%) and 21 (38.2%) of 55 serum samples from SLE patients without B19 DNA respectively. Parvovirus B19 DNA was found more often in SLE patients without anti-B19 IgG and IgM than in those with anti-B19 IgG and IgM antibodies (P < 0.05). The structures of the B19 DNA fragments generated by nested PCR were analysed by the use of the restriction endonucleases AluI and AcsI. The sizes of the enzyme cleavage products for AluI were 56, 63, 123 and 199 bp and those for AcsI were 33, 55, 88 and 234 bp (Fig. 2) . For the con®rmation of these 22 positive samples with B19 DNA by nested PCR, southern blot analysis was employed. The B19SIII oligonucleotide probe, which anneals at nucleotides 2541±2564 for B19 and is known to be an important epitope region w31±33x, was endlabelled with w 32 PxATP and hybridized with the nylon membrane containing the PCR products. The results of southern blotting showed that the 22 samples were all B19-positive (Fig. 3B) . As shown in Fig. 3A and B, lanes 2±12 were positive for 322 bp PCR products. 
Clinical signi®cance of parvovirus B19 infection in patients with SLE
The relationship between the presence of B19 DNA and clinical manifestations of SLE was studied. As shown in Table 2 , the prevalence of hypocomplementaemia was higher in patients with B19 viraemia. No correlation could be found between the presence of B19 DNA and other clinical manifestations of SLE.
Discussion
The relationship of parvovirus B19 infection with SLE is an issue of interest. There are striking similarities between B19 infection and SLE. It is dif®cult to differentiate B19 infection from SLE clinically. The occurrence of parvovirus B19 infection in adults has been documented in some patients with systemic autoimmune diseases w5, 6, 16±19x. Parvovirus B19 may be accompanied by a transient subclinical state of autoimmunity w22x and may mimic or exacerbate SLE w6, 21x. It may be implicated in the development of SLE as well as other chronic arthropathies w5, 22x. In our study, parvovirus B19 DNA was detected in 17 (24%) patients with SLE by PCR and was con®rmed by Southern blotting. B19 DNA was not found in sera from patients with other autoimmune diseases, including RA, SS, PBC and PM. However, the presence of B19 DNA in patients with SLE may not be causative. It may rather re¯ect a superimposed B19 infection in patients with SLE due to lack of antibodies against B19. In this study, the prevalence of IgG and IgM anti-B19 antibodies in sera from SLE patients with B19 DNA was much lower than in patients without B19 DNA (P < 0.05). Kurtzman et al. w14, 34x demonstrated that the production of antibody to the B19 capsid protein plays a major role in limiting parvovirus infection in man. It has also been reported that, in the immunocompetent host, the production of B19-speci®c antibodies results in clearance of the viraemia within a few days, whereas in immunocompromised patients the virus persists w14, 34±35x. The appearance of B19-speci®c neutralizing antibodies might alter the course of viral infection. The persistence of infection with parvovirus B19 in our patients with SLE may have been due to lack of antibodies against parvovirus B19 because the host was immunocompromised or because of the use of immunosuppressive agents. Numbers in parentheses are percentages. CNS = central nervous system; ESR = erythrocyte sedimentation rate; ANA = antinuclear antibodies; anti-dsDNA = anti-doublestranded DNA; anti-ENA = anti-extractable nuclear antigens; AST = aspartate aminotransferase; ALT = alanine aminotransferase; aCL = anti-cardiolipin antibody.
The restriction mapping of nested PCR product is a simple and sensitive method of detecting B19 infection that is suitable for clinical use. The typical pro®les of AluI and AcsI cleavage products with four different DNA fragments (Fig. 2) are both easily identi®ed for the con®rmation of B19 infection. The method gives consistent results and can be used instead of nucleotide sequencing to con®rm B19 infection.
As B19 DNA was detected only in patients with SLE or EI, its clinical signi®cance was studied further. Hypocomplementaemia and RP were signi®cantly more common in patients with B19 viraemia than in those without B19 DNA. Parvovirus B19 infection may have exacerbated the clinical course of SLE. However, there was no apparent association between the presence of B19 DNA and other clinical manifestations, such as skin rash, arthritis and proteinuria, in patients with SLE. Recently, cytomegalovirus infection has been found to be a highly signi®cant risk factor for RP w36x. Viral infection may affect the course of SLE, leading to speci®c clinical subsets. These preliminary ®ndings require con®rmation in order to elucidate the signi®cance of the presence of B19 DNA in SLE.
